News
Amgen's Soliris biosimilar clears phase 3, but won't launch ...
Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA.
